RxDoctor Payments Data

David Chase, MD

Pulmonary Disease · Booneville, MSNPI 1588623532

Payments from drug & device makers

$725in general payments, 2019–2025

Across 37 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$158
  • Boehringer Ingelheim$124
  • Insmed, Inc.$109
  • GSK$100
  • AstraZeneca$77
  • Regeneron Healthcare Solutions, Inc.$62
  • plus $95 from 4 others

What the payments were for

  • Food & beverage$66792%
  • Education$588%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$725 in reported general payments places this provider in the 20th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$538,944
Medicare patients
1,521
Services billed
8,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter825$560,257
ZemairaAlpha-1-Proteinase Inhibitor12$131,522
EsbrietPirfenidone12$123,383
Breztri AerosphereBudesonide/Glycopyr/Formoterol109$78,106
EliquisApixaban42$26,713
Spiriva HandihalerTiotropium Bromide27$15,220
Breo ElliptaFluticasone/Vilanterol36$15,007
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$14,675
Theophylline ErTheophylline Anhydrous440$14,362
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$14,193
Spiriva RespimatTiotropium Bromide17$12,875
Incruse ElliptaUmeclidinium Bromide25$12,593
Varenicline Tartrate49$11,404
DuleraMometasone/Formoterol28$10,858
Albuterol Sulfate HfaAlbuterol Sulfate324$8,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$100$602,051915 claims
AstraZenecaBreztri Aerosphere, Symbicort$77$85,294140 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$124$27,55039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Booneville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →